Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery
Stocks in this Quantisnow insightHealth Care
Historical context for NOTV
Across the 6 sessions after earlier NOTV headlines, the stock closed higher 2 times and lower 4 times, with a median move of 4.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NOTV | SPY |
|---|---|---|---|
| Dec 11, 2025 | Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities | -4.5% | +0.2% |
| Dec 4, 2025 | Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update | -6.5% | +0.1% |
| Nov 25, 2025 | Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™ | +3.9% | +0.9% |
| Nov 21, 2025 | Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025 | -3.9% | +1.0% |
| Nov 18, 2025 | Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results | +24.6% | -0.8% |
| Oct 22, 2025 | Inotiv, Inc. to Participate in Three Investor Conferences in November 2025 | -2.2% | -0.5% |
Quantisnow market dataNASDAQ
NOTV
Inotiv Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
Get push alerts for NOTV
Full NOTV profile on Quantisnow Follow NOTV and get a push notification the moment its next story breaks.